Rheumatoid arthritis, TNF inhibitors, and non-melanoma skin cancer

  title={Rheumatoid arthritis, TNF inhibitors, and non-melanoma skin cancer},
  author={Shervin Assassi},
  journal={British Medical Journal},
  • S. Assassi
  • Published 2016
  • Medicine
  • British Medical Journal
Most of the excess risk is related to the disease, not the treatment 
Rheumatoid Arthritis, Anti–Tumor Necrosis Factor Treatment, and Skin Cancer
Tumor necrosis factor α (TNF-α) inhibitors, a mainstay of biologic therapy for psoriasis, psoriatic arthritis, rheumatoid arthritis (RA), and
Anti-TNF Therapy in Spondyloarthritis and Related Diseases, Impact on the Immune System and Prediction of Treatment Responses
A review of efforts dedicated to identify biomarkers that can predict treatment responses to TNFi and a section dedicated to the recently introduced inhibitors of IL-17A and IL-23 in SpA and related diseases. Expand
Rheumatoid arthritis – an update for general dental practitioners
Information is provided on RA, oral health in RA and guidance on how best to manage patients with RA in general dental practice and how to diagnose and treat co-morbidities. Expand
Risk of Malignant Neoplasm in Patients with Incident Rheumatoid Arthritis 1980–2007 in relation to a Comparator Cohort: A Population-Based Study
Whether the incidence of malignancy is increased in patients with rheumatoid arthritis compared to a matched comparison cohort and to identify risk for any individual malignancies in RA is determined. Expand
Nanoparticle-siRNA: A potential strategy for rheumatoid arthritis therapy?
  • N. Feng, F. Guo
  • Medicine
  • Journal of controlled release : official journal of the Controlled Release Society
  • 2020
The pathogenesis of RA is summarized as a possible target for small interference RNA (siRNA) design and the nanoparticles used in siRNA carriers in recent years are analyzed, laying the foundation and prospect for the next step in the development of intelligent nanocarriers. Expand
Systematic review of the real‐world evidence of adalimumab safety in psoriasis registries
It is suggested that real‐world safety of adalimumab is consistent across different psoriasis registries, which supports the existing long‐term safety profile of adAlimumab from clinical studies. Expand
Study on association of HSP70_hom gene polymorphism with rheumatoid arthritis using capillary electrophoresis-laser induced fluorescence
The method of CE-LIF detection had the advantages of rapid analysis, high resolution and environmental friendliness, and could be applied to the detection of gene polymorphism; HSP70_hom gene polymorphisms was not significantly associated with rheumatoid arthritis. Expand


Incidences of overall and site specific cancers in TNFα inhibitor treated patients with rheumatoid arthritis and other arthritides – a follow-up study from the DANBIO Registry
The results suggest that TNF-I therapy in routine care is not associated with an overall excess of cancer in arthritis patients, but observed increased risks of colon and ovarian cancer need further investigation. Expand
Risk of non-melanoma skin cancer in a national cohort of veterans with rheumatoid arthritis.
TNF- α antagonist therapy in veterans with RA may be associated with an increased risk of NMSC, compared with therapy with non-biologic DMARDs, and rheumatologists should carefully screen patients receiving TNF-α antagonists for pre-cancerous skin lesions and skin cancer. Expand
Tumor necrosis factor α inhibitor therapy and cancer risk in chronic immune-mediated diseases.
Short-term cancer risk was not elevated among patients treated with TNFα inhibitor therapy relative to commonly used therapies for immune- mediated chronic inflammatory diseases in this study. Expand
Rheumatoid arthritis and cancer risk.
There seem to be consistent positive associations between RA and non-Hodgkin's lymphoma, Hodgkin's disease and lung cancer and a consistent negative association with colorectal cancer. Expand
Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: meta‐analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data
This meta‐analysis aimed at better assessing short‐term risks by using meta‐analytic techniques based on individual patient data from all corporate‐sponsored randomized controlled trials (RCTs) of adalimumab, etanercept, and infliximab. Expand
Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists
The cancer pattern in patients treated with TNF antagonists mirrors those of other contemporary as well as historic RA cohorts, and the consistent increase in smoking associated cancers in patients with RA emphasises the potential for smoking cessation as a cancer preventive measure in RA. Expand
The Netherlands
Specialised psychiatric nurses in Amsterdam are helping to combat the spread of AIDS among drug addicts in the Dutch capital.
Rheumatoid arthritis, anti-tumour necrosis factor treatment, and risk of squamous cell and basal cell skin cancer: cohort study based on nationwide prospectively recorded data from Sweden
A small to moderately increased risk of basal cell cancer was seen in biologics-naive rheumatoid arthritis patients, with no further effect of TNF inhibitors. Expand
British Society for Rheumatology Biologics Register
The British Society for Rheumatology established a register of patients newly treated with biological agents, the BSR Biologics Register (BSRBR), which became active in January 2002 and is recruiting a comparison cohort of patients with rheumatoid arthritis treated with standard disease modifying antirheumatic drugs. Expand
Incidence of skin cancer after renal transplantation in The Netherlands.
The overall risk to develop a first tumor increased from 10% after 10 years to 40% after 20 years of graft survival, and the overall incidence was 250 times higher and that of BCC 10 times higher when compared with the general Dutch population. Expand